Thera-SAbDab

FICLATUZUMAB

>   Structural Summary
TherapeuticFiclatuzumab
TargetHGF
Heavy ChainQVQLVQPGAEVKKPGTSVKLSCKASGYTFTTYWMHWVRQAPGQGLEWIGEINPTNGHTNYNQKFQGRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNYVGSIFDYWGQGTLLTVSS
Light ChainDIVMTQSPDSLAMSLGERVTLNCKASENVVSYVSWYQQKPGQSPKLLIYGASNRESGVPDRFSGSGSATDFTLTISSVQAEDVADYHCGQSYNYPYTFGQGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2011
INN Year Recommended2012
Companies InvolvedAVEO Oncology, AVEO Pharmaceuticals, Dana-Farber Cancer Institute, University of Arizona Cancer Center, University of California at San Francisco
Conditions Approvedna
Conditions ActiveHead and neck cancer, Non-small cell lung cancer, Acute myeloid leukaemia, Pancreatic cancer
Conditions DiscontinuedLymphoma, Multiple myeloma, Solid tumours, Glioblastoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]